CTOs on the Move

Aphria

www.aphria.com

 
Founded in 2013, Aphria is integrating their growing expertise with Health Canada`s new Access to Cannabis for Medical Purposes Regulations (ACMPR) for the medicinal marijuana industry. Possessing greenhouse related growing experience in plant and produce related expertise since 1943, Aphria is positioned to be an industry leader in providing patients with the highest quality medical marijuana. Aphria has developed integrated greenhouse growing solutions specifically focused on quality production of cannabis. With the authorization of quantity scale marijuana growing, Aphria greenhouse operations are a natural fit. Aphria is a licensed producer of Medicinal Marijuana under the Health Canada Regulations. Grown in ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.aphria.com
  • 35 McCaul St. Suite 201
    Toronto, ON CAN M5T 1V7
  • Phone: 833.254.4877

Executives

Name Title Contact Details

Funding

Aphria raised $80M on 12/02/2019

Similar Companies

Ridgmar Pharmacy

Ridgmar Pharmacy is a Fort Worth, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

STERIS IMS

STERIS Instrument Management Services is a surgical device and instrument management and consulting company.

Canadian Phamacy Online

Canadian Phamacy Online is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has four product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome. GCS-100 is La Jolla’s first-in-class galectin-3 inhibitor for the potential treatment of chronic kidney disease. LJPC-1010, La Jolla’s second-generation galectin-3 inhibitor, is a more potent and purified derivative of GCS-100 that can be delivered orally for the potential treatment of nonalcoholic steatohepatitis and other diseases characterized by tissue fibrosis. LJPC-401 is La Jolla’s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hemochromatosis and beta thalassemia

Clinuvel

Clinuvel is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.